NUVB vs. SAGE, WVE, NRIX, PAHC, COGT, AUPH, PRTC, CVAC, ANAB, and GHRS
Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Sage Therapeutics (SAGE), Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), Phibro Animal Health (PAHC), Cogent Biosciences (COGT), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), CureVac (CVAC), AnaptysBio (ANAB), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Nuvation Bio (NYSE:NUVB) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Nuvation Bio has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
In the previous week, Nuvation Bio had 6 more articles in the media than Sage Therapeutics. MarketBeat recorded 11 mentions for Nuvation Bio and 5 mentions for Sage Therapeutics. Nuvation Bio's average media sentiment score of 0.49 beat Sage Therapeutics' score of 0.31 indicating that Nuvation Bio is being referred to more favorably in the media.
Nuvation Bio has a net margin of 0.00% compared to Sage Therapeutics' net margin of -552.52%. Nuvation Bio's return on equity of -11.31% beat Sage Therapeutics' return on equity.
Nuvation Bio has higher earnings, but lower revenue than Sage Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nuvation Bio currently has a consensus target price of $6.60, indicating a potential upside of 105.61%. Sage Therapeutics has a consensus target price of $37.67, indicating a potential upside of 218.94%. Given Sage Therapeutics' higher possible upside, analysts plainly believe Sage Therapeutics is more favorable than Nuvation Bio.
Sage Therapeutics received 594 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 72.73% of users gave Nuvation Bio an outperform vote while only 67.82% of users gave Sage Therapeutics an outperform vote.
Summary
Nuvation Bio beats Sage Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Nuvation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvation Bio Competitors List
Related Companies and Tools
